Zevra Therapeutics Secures 2041 Patent Protection for MIPLYFFA via Orange Book Listing
Event summary
- Zevra Therapeutics added U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the FDA’s Orange Book, extending exclusivity to November 19, 2041.
- A separate patent term extension for U.S. Patent No. 11,045,460 (currently expiring in 2029) remains pending with the USPTO.
- MIPLYFFA is indicated for Niemann-Pick disease type C (NPC), an ultra-rare neurodegenerative disorder.
- The Orange Book listing strengthens Zevra’s intellectual property defenses against generic competition.
The big picture
Zevra’s Orange Book listing reinforces its control over the MIPLYFFA market, a critical move in the rare disease space where patent protection often dictates long-term commercial viability. The pending extension for another patent suggests a strategic push to maximize exclusivity, a key factor for investors assessing the sustainability of Zevra’s revenue stream from this ultra-rare disease therapy.
What we're watching
- Patent Strategy
- Whether the pending patent term extension for U.S. Patent No. 11,045,460 will further extend MIPLYFFA’s market exclusivity beyond 2029.
- Competitive Barriers
- How the Orange Book listing will impact Zevra’s ability to fend off potential generic or biosimilar challengers.
- Commercialization
- The pace at which Zevra can expand MIPLYFFA’s geographic reach and patient access in the NPC market.